<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609111</url>
  </required_header>
  <id_info>
    <org_study_id>Y0080</org_study_id>
    <nct_id>NCT04609111</nct_id>
  </id_info>
  <brief_title>ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study</brief_title>
  <acronym>STOPDAPT-3</acronym>
  <official_title>ShorT and OPtimal Duration of Dual AntiPlatelet Therapy Study After Everolimus-eluting Cobalt-chromium Stent-3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University, Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the benefit of the prasugrel monotherapy without&#xD;
      aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of&#xD;
      reducing bleeding events after percutaneous coroanry intervention (PCI) using cobalt-chromium&#xD;
      everolimus-eluting stents (CoCr-EES, XienceTM) in patients with high bleeding risk or under&#xD;
      the acute coronary syndrome patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the previous trial, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel&#xD;
      monotherapy provided a net clinical benefit for the cardiovascular and bleeding events over&#xD;
      12-month DAPT with aspirin and clopidogrel after cobalt-chromium everolimus-eluting stent&#xD;
      (CoCr-EES) implantation. However, even with very short DAPT, the rate of bleeding at 1-year&#xD;
      remained very high in other trials that enrolled the patients with high bleeding risk (HBR).&#xD;
      Notably, the risk of bleeding in patients with high bleeding risk (HBR) was particularly high&#xD;
      within 1-month after percutaneous coronary intervention (PCI) in previous chort data, when&#xD;
      DAPT is implemented even in very short DAPT regimen. More recently, in another trial,&#xD;
      prasugrel monotherapy without aspirin immediately after successful stent implantation was&#xD;
      associated with no stent thrombosis in selected patients with low risk stable coronary artery&#xD;
      disease. Aspirin-free strategy might be particularly beneficial in reducing bleeding in HBR&#xD;
      patients. Patients with acute coronary syndrome (ACS) are also reported to be associated with&#xD;
      higher risk for bleeding.&#xD;
&#xD;
      Therefore, we have planned a study to compare the cardiovascular and bleeding events at&#xD;
      1-month after PCI using CoCr-EES between no DAPT strategy and 1-month DAPT strategy in&#xD;
      patients with HBR or ACS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>1 month</time_frame>
    <description>Bleeding defined as BARC criteria 3 or 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular composite endpoint</measure>
    <time_frame>1 month</time_frame>
    <description>Composite of cardiovascular death, myocardial infarction, ischemic stroke ,or definite stent thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1 month</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>1 month</time_frame>
    <description>Death from cardiac or vascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>12 months</time_frame>
    <description>Death from cardiac or vascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 month</time_frame>
    <description>Defined by arterial revascularization therapies study (ARTS) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>12 months</time_frame>
    <description>Defined by arterial revascularization therapies study (ARTS) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>1 month</time_frame>
    <description>Including both ischemic and heamorrhagic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Including both ischemic and heamorrhagic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>1 month</time_frame>
    <description>Ischemic stroke with symptom lasting over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Ischemic stroke with symptom lasting over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>1 month</time_frame>
    <description>Intracerebral hemorrhage or subarchnoidal hemorrhage not associated with trauma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Intracerebral hemorrhage or subarchnoidal hemorrhage not associated with trauma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 month</time_frame>
    <description>Stent thrombosis defined by Academic Research Consortium definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Stent thrombosis defined by Academic Research Consortium definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>1 month</time_frame>
    <description>The angiographical confirmation of the restnosis of the target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>12 months</time_frame>
    <description>The angiographical confirmation of the restnosis of the target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>1 month</time_frame>
    <description>The angiographical confirmation of the restnosis or new lesion(s) of the target vessels or myocardial infarction involving the teritory of target vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>12 months</time_frame>
    <description>The angiographical confirmation of the restnosis or new lesion(s) of the target vessels or myocardial infarction involving the teritory of target vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any target lesion revascularization</measure>
    <time_frame>1 month</time_frame>
    <description>Revascularization to the target lesions (including 5mm of both ends of the stent(s)) regardless of PCI or CABG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Revascularization to the target lesions (including 5mm of both ends of the stent(s)) regardless of PCI or CABG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven target lesion revascularization</measure>
    <time_frame>1 month</time_frame>
    <description>Target lesion revascularization with the anginal symptoms or the positive test for ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Target lesion revascularization with the anginal symptoms or the positive test for ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target lesions revascularization</measure>
    <time_frame>1 month</time_frame>
    <description>Revascularization to non-target lesions regardlesspercutaneous coronary intervention or coronary artery bypass grafting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target lesions revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Revascularization to non-target lesions regardless percutaneous coronary intervention or coronary artery bypass grafting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery bypass grafting</measure>
    <time_frame>1 month</time_frame>
    <description>Any coronary artery bypass grafting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery bypass grafting</measure>
    <time_frame>12 months</time_frame>
    <description>Any coronary artery bypass grafting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any target vessel revascularization</measure>
    <time_frame>1 month</time_frame>
    <description>Revascularization to the target vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any target vessel revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Revascularization to the target vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any coronary revascularization</measure>
    <time_frame>1 month</time_frame>
    <description>Revascularization regardless of percutaneous coronary intervention or coronary artery bypass grafting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any coronary revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Revascularization regardless of percutaneous coronary intervention or coronary artery bypass grafting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 2 bleeding in Bleeding Academic Research Consortium (BARC) criteria</measure>
    <time_frame>1 month</time_frame>
    <description>Type 2 bleeding defined by BARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 2 bleeding in Bleeding Academic Research Consortium (BARC) criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Type 2 bleeding defined by BARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 3 bleeding in Bleeding Academic Research Consortium (BARC) criteria</measure>
    <time_frame>1 month</time_frame>
    <description>Type 3 bleeding defined by BARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 3 bleeding in Bleeding Academic Research Consortium (BARC) criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Type 3 bleeding defined by BARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 4 bleeding in Bleeding Academic Research Consortium (BARC) criteria</measure>
    <time_frame>1 month</time_frame>
    <description>Type 4 bleeding defined by BARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 4 bleeding in Bleeding Academic Research Consortium (BARC) criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Type 4 bleeding defined by BARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 5 bleeding in Bleeding Academic Research Consortium (BARC) criteria</measure>
    <time_frame>1 month</time_frame>
    <description>Type 5 bleeding defined by BARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 5 bleeding in Bleeding Academic Research Consortium (BARC) criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Type 5 bleeding defined by BARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 2, 3, or 5 bleeding in Bleeding Academic Research Consortium (BARC) criteria</measure>
    <time_frame>1 month</time_frame>
    <description>Type 2, 3, or 5 bleeding defined by BARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 2, 3, or 5 bleeding in Bleeding Academic Research Consortium (BARC) criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Type 2, 3, or 5 bleeding defined by BARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria</measure>
    <time_frame>1 month</time_frame>
    <description>Major bleeding defined by TIMI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Major bleeding defined by TIMI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria</measure>
    <time_frame>1 month</time_frame>
    <description>Minor bleeding defined by TIMI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Minor bleeding defined by TIMI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or minor bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria</measure>
    <time_frame>1 month</time_frame>
    <description>Major or minor defined by TIMI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or minor bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Major or minor defined by TIMI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe bleeding in Global Utilization Of Streptokinase And Tpa For Occluded Arteries (GUSTO) criteria</measure>
    <time_frame>1 month</time_frame>
    <description>Severe bleeding defined by GUSTO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe bleeding in Global Utilization Of Streptokinase And Tpa For Occluded Arteries (GUSTO) criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Severe bleeding defined by GUSTO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate bleeding in Global Utilization Of Streptokinase And Tpa For Occluded Arteries (GUSTO) criteria</measure>
    <time_frame>1 month</time_frame>
    <description>Moderate bleeding defined by GUSTO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate bleeding in Global Utilization Of Streptokinase And Tpa For Occluded Arteries (GUSTO) criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Moderate bleeding defined by GUSTO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate or severe bleeding in Global Utilization Of Streptokinase And Tpa For Occluded Arteries (GUSTO) criteria</measure>
    <time_frame>1 month</time_frame>
    <description>Moderate or severe bleeding defined by GUSTO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate or severe bleeding in Global Utilization Of Streptokinase And Tpa For Occluded Arteries (GUSTO) criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Moderate or severe bleeding defined by GUSTO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial bleeding</measure>
    <time_frame>1 month</time_frame>
    <description>Intracranial bleeding regardless of spontaneous or trauma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Intracranial bleeding regardless of spontaneous or trauma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal bleeding</measure>
    <time_frame>1 month</time_frame>
    <description>Bleeding from gastrointestinal tract regardless of severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Bleeding from gastrointestinal tract regardless of severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal complaints</measure>
    <time_frame>1 month</time_frame>
    <description>Requirement of upper gastric fiberscopy to examine the gastrointestinal complaints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal complaints</measure>
    <time_frame>12 months</time_frame>
    <description>Requirement of upper gastric fiberscopy to examine the gastrointestinal complaints</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3110</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>No aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To start prasugrel monotherapy before the index percutaneous coronary intervention (PCI) and to change into clopidogrel monotherapy at 1-month after the PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1-month DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To start dual antiplatelet therapy comprising of aspirin and prasugrel before the index percutaneous coronary intervention (PCI) and to change into aspirin monotherapy at 1-month after the PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No aspirin</intervention_name>
    <description>1-month prasugrel monotherapy followed by clopidogrel monotherapy</description>
    <arm_group_label>No aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1-month DAPT</intervention_name>
    <description>1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy</description>
    <arm_group_label>1-month DAPT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are planned to have percutaneous coronary intervention with exclusive use&#xD;
             of everolimus-eluting stent (XienceTM series).&#xD;
&#xD;
          -  Patients with high bleeding risk defined by Academic Research Consortium or acute&#xD;
             coronary syndrome&#xD;
&#xD;
          -  Patients who could take dual antiplatelet therapy with aspirin and P2Y12 inhibitors&#xD;
             for 1-month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Kimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyoto University, Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeshi Kimura, MD</last_name>
    <phone>+81-75-751-4254</phone>
    <email>taketaka@kuhp.kyoto-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyoto University Graduate School of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takeshi Kimura, MD</last_name>
      <phone>+81-75-751-4254</phone>
      <email>taketaka@kuhp.kyoto-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takeshi Kimura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Takeshi Morimoto</investigator_full_name>
    <investigator_title>Study Statistician</investigator_title>
  </responsible_party>
  <keyword>stent</keyword>
  <keyword>percutaneous coronary transluminal angioplasty</keyword>
  <keyword>bleeding</keyword>
  <keyword>antiplatelet agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

